A machine-learning model using structured multifrequency bioimpedance descriptors identified previously diagnosed diabetes with an AUROC of 0.8336 in a proof-of-concept study.

The Portable Bioimpedance Analyzer market was valued at USD 1.2 billion in 2025 and is poised to grow from USD 1.

The Portable Bioimpedance Analyzer market was valued at USD 1.2 billion in 2025 and is poised to grow from USD 1.

Moving bioimpedance displays from the floor to eye level signals a broader commoditization of advanced home health metrics.

US Bioimpedance Analyzers Market share register 126.85 USD Million in 2024, projected to grow 10.65 % CAGR to reach USD Million 386.13 during the forecast period 2025 - 2035.

Germany Bioimpedance Analyzers Market share register 28.32 USD Million in 2024, projected to grow 11.11 % CAGR to reach USD Million 90.21 during the forecast period 2025 - 2035.

First announced all the way back at CES in January, the Withings Body Scan 2 is now available to purchase in Australia, alongside the new BodyFit Scale. The two scales are pitched at different people. The BodyScan 2 is the flagship, aimed at anyone who wants a long-term picture of their heart and metabolic health. The BodyFit is the cheaper option, built around body composition and training progress. Both use 13-frequency bioimpedance spectroscopy. That means the scale sends tiny electrical currents through your body at different frequencies to estimate how much of you is muscle, fat and water. Both also split that reading into six zones across your arms, legs, trunk and core, so you can see where you're gaining muscle or losing fat. Withings says the scales show up to 99% correlation with DEXA scans for fat mass. Withings Chairman and Co-founder Eric Carreel said the goal is to get people looking past the number on the display. > _"When we rely on standard scales, we let a single number dictate how we feel about our health, but the weight is just a number. True longevity and vitality come from understanding what is happening inside the body."_ ## Withings BodyScan 2 A full BodyScan 2 reading takes 90 seconds. You stand on the scale and hold a retractable handle, which has a colour display that shows your results as they come in. Compared with the original Body Scan, the BodyScan 2 jumps from three bioimpedance frequencies to 13 and splits body composition into six zones instead of three. It also adds blood oxygen, impedance cardiography for Heart Age and the screen in the handle, where the original only had a display on the platform. That handle also houses a 6-lead ECG that can detect signs of atrial fibrillation. The ECG is included on the Australian Register of Therapeutic Goods, so it's a regulated medical feature rather than a wellness estimate. If heart tracking is your main interest, it's worth comparing with what the latest Apple Watches can do for heart health. There's also a PPG sensor for blood oxygen, visceral fat tracking, a Heart Age estimate and a Nerve Response Score. That last one feeds into a metric Withings calls Glucose Resilience. There are two catches. Heart Age and Glucose Resilience sit behind Withings+, the app's paid subscription, and the BodyScan 2 only includes a one month trial. Hypertension notifications are also missing at launch. The feature is still under TGA review, and Withings says it will switch on once it's cleared. ## Withings BodyFit The BodyFit skips the handle and ECG, and gets a body composition reading done in around 20 seconds. Withings says it tracks visceral fat and more than 40 biomarkers, including muscle, fat and hydration trends. A new Body Profile feature swaps BMI for a 16-zone matrix based on your skeletal muscle and fat mass indexes, calibrated for age and sex. It then gives you a label like Athletic, Strong or Powerhouse, which will either motivate you or annoy you. BodyPath estimates your calorie balance from body composition changes over time. It links your weight target to your daily activity, sleep and nutrition habits. Withings hasn't said which third-party devices feed into that, so don't assume your smartwatch or Oura Ring will play along. Withings is aiming that at people on structured weight-loss programs who want to check they're losing fat while keeping muscle. ## Specs | Withings BodyScan 2 | Withings BodyFit ---|---|--- RRP | $899.99 | $499.99 Scan time | 90 seconds | Around 20 seconds Body composition | 13-frequency bioimpedance spectroscopy, six-zone segmental analysis | 13-frequency bioimpedance spectroscopy, six-zone segmental analysis DEXA correlation (claimed) | Up to 99% (fat mass) | Up to 99% (fat mass), up to 98% (muscle mass) Visceral fat | Yes | Yes ECG | 6-lead, AFib detection | Not listed Blood oxygen | Yes (PPG sensor) | Not listed Heart Age and Glucose Resilience | Yes (Withings+ subscription required) | Not listed Hypertension notifications | Pending TGA clearance | Not listed Body Profile and BodyPath | Not listed | Yes Display | High-resolution colour screen in retractable handle | Not listed Withings+ trial | One month included | Not listed App | Withings app | Withings app ## Pricing and availability The Withings BodyScan 2 is available now in Australia for $899.99, while the BodyFit costs $499.99. * * * ### Latest medical device deals

South America bioimpedance analyzers Market size is projected to reach USD 130 Million by 2035 from USD 49.86 Million in 2025, at a CAGR of 10.0% during the forecast 2025–2035.

Bioimpedance Analyzers Market size is projected to reach USD 1.359 Billion by 2035 from USD 0.501 Billion in 2025, at a CAGR of 10.5% during the forecast 2025–2035.

📅 Publication Date: September 2026 | ⏳ Forecast Period: 2026-2033 📊 Market Intelligence Overview | Get the full PDF sample copy of the report: (Includes full table of contents, list of tables and figu...

UCL Discovery is UCL's open access repository, showcasing and providing access to UCL research outputs from all UCL disciplines.

The France Bioimpedance Analyzers market is projected to grow from USD Million 16.99 in 2024 to USD Million 51.13 by 2035, at a CAGR of 10.54% during 2025-2035.

The Spain Bioimpedance Analyzers market is projected to grow from USD Million 11.33 in 2024 to USD Million 39.77 by 2035, at a CAGR of 12.09% during 2025-2035.

The Italy Bioimpedance Analyzers market is projected to grow from USD Million 11.33 in 2024 to USD Million 40.0 by 2035, at a CAGR of 12.15% during 2025-2035.

The China Bioimpedance Analyzers market is projected to grow from USD Million 22.65 in 2024 to USD Million 67.93 by 2035, at a CAGR of 10.5% during 2025-2035.

The India Bioimpedance Analyzers market is projected to grow from USD Million 18.12 in 2024 to USD Million 55.21 by 2035, at a CAGR of 10.66% during 2025-2035.

Market Snapshot of the United States Single-frequency Bioimpedance Devices Market Market size (2024): Approximately USD 1.2 billion, driven by technological advancements and increasing adoption in cli...